Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance
Site Search
The Cystic Fibrosis Foundation awarded up to $4.7 million to EnBiotix Inc. to study the potential use of inhaled colistin as an additional option to treat Pseudomonas infections in people with cystic fibrosis who are not responding to current treatments.
The Cystic Fibrosis Foundation awarded up to $3.5 million to Arrevus Inc. to test a potential treatment for pulmonary exacerbations in people with cystic fibrosis in a late phase clinical trial.
Observational study supported by the CF Foundation will monitor real-world experience with Trikafta
Study reaffirms the Foundation's commitment to advance solutions to the growing challenge of antibiotic resistance and evaluate the use of phage to treat infections for people with CF
CF Foundation national and local events, provide your company with opportunities to align with a results-driven organization and better position your brand.
A new law that allows patients with rare diseases to participate in clinical trials without losing eligibility for public health care benefits went into effect yesterday. The bill, known as the “Improving Access to Clinical Trials Act” (IACT), was championed by the Cystic Fibrosis Foundation and signed into law in October 2010.
The 23rd annual Ultimate Golf Experience (UGE) brought together a star-studded lineup of entertainers and friends, who gathered in Newport Coast, Calif. to raise funds in the fight against cystic fibrosis.
Watch the entire leadership conference, including all of the break-out sessions and Medical Hot Topics, from start to finish.
Support our mission with a grant: We welcome support from private, corporate, and family foundations.